Treatment options for severe sepsis and septic shock

References

• Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit. Care Med.29, S109–S116 (2001).
   PubMed Web of Science ®Google Scholar
• Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med.348, 1546–1554 (2003).
   PubMed Web of Science ®Google Scholar
• Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time? Crit. Care Med.26, 2078–2086 (1998).
   PubMed Web of Science ®Google Scholar
• Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA273, 117–123 (1995).
   PubMed Web of Science ®Google Scholar
• Meehan TP, Fine MJ, Krumholz HM et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA278,2080–2084 (1997).
   PubMed Web of Science ®Google Scholar
• Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest122, 262–268 (2002).
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Carlet JM, Masur et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med.32, 858–873 (2004).
   PubMed Web of Science ®Google Scholar
• Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest115, 462–474 (1999).
   PubMed Web of Science ®Google Scholar
• Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest118, 146–155 (2000).
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit. Care Med.31, 2742–2751 (2003).
   PubMed Web of Science ®Google Scholar
• Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest123, 1615–1624 (2003).
   PubMed Web of Science ®Google Scholar
• Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit. Care Med.29, 1109–1115 (2001).
   PubMed Web of Science ®Google Scholar
• Jimenez MF, Marshall JC; International Sepsis Forum. Source control in the management of sepsis. Intensive Care Med.27(Suppl. 1), S49–S62 (2001).
   PubMed Web of Science ®Google Scholar
• Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Br. Med. J.317, 235–240 (1998).
   PubMed Web of Science ®Google Scholar
• Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann. Intern. Med.135, 149–164 (2001).
   PubMed Web of Science ®Google Scholar
• Roberts I, Alderson P, Bunn F, Chinnock P, Ker K, Schierhout G. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst. Rev.4, CD000567 (2004).
   Google Scholar
• Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N. Engl. J. Med.350, 2247–2256 (2004).
   PubMed Web of Science ®Google Scholar
• Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med.345, 1368–77 (2001).
   PubMed Web of Science ®Google Scholar
• Hebert PC, Wells G, Blajchman MA et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N. Engl. J. Med.340, 409–417 (1999).
   PubMed Web of Science ®Google Scholar
• Hayes MA, Timmins AC, Yau EH et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N. Engl. J. Med.330, 1717–1722 (1994).
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Brazzi L, Pelosi P et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N. Engl. J. Med.333, 1025–1032 (1995).
   PubMed Web of Science ®Google Scholar
• LeDoux D, Astiz ME, Carpati CM, Rackow EC. Effects of perfusion pressure on tissue perfusion in septic shock. Crit. Care Med.28, 2729–2732 (2000).
   PubMed Web of Science ®Google Scholar
• Ract C, Vigue B. Comparison of the cerebral effects of dopamine and norepinephrine in severely head-injured patients. Intensive Care Med.27, 101–106 (2001).
   PubMed Web of Science ®Google Scholar
• van den Berghe G, de Zegher F. Anterior pituitary function during critical illness and dopamine treatment. Crit. Care Med.24, 1580–1590 (1996).
   PubMed Web of Science ®Google Scholar
• Ruokonen E, Takala J, Kari A, Saxen H, Mertsola J, Hansen EJ. Regional blood flow and oxygen transport in septic shock. Crit. Care Med.21, 1296–1303 (1993).
   PubMed Web of Science ®Google Scholar
• Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA272, 1354–1357 (1994).
   PubMed Web of Science ®Google Scholar
• Neviere R, Mathieu D, Chagnon JL, Lebleu N, Wattel F. The contrasting effects of dobutamine and dopamine on mucosal perfusion in septic patients. Am. J. Respir. Crit. Care Med.154, 1684–1688 (1996).
   PubMed Web of Science ®Google Scholar
• De Backer D, Creteur J, Silva E, Vincent JL. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit. Care Med.31, 1659–1667 (2003).
   PubMed Web of Science ®Google Scholar
• Meadows D, Edwards JD, Wilkins RG et al. Reversal of intractable septic shock with norepinephrine therapy. Crit. Care Med.16, 663–667 (1988).
   PubMed Web of Science ®Google Scholar
• Schreuder WO, Schneider AJ, Groeneveld ABJ et al. Effect of dopamine vs norepinephrine on hemodynamics in septic shock. Chest95, 1282–1288 (1989).
   PubMed Web of Science ®Google Scholar
• Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock. Chest103, 1826–1831 (1993).
   PubMed Web of Science ®Google Scholar
• Martin C, Viviand X, Leone M, Thirion X. Effect of norepinephrine on the outcome of septic shock. Crit. Care Med.28, 2758–2765 (2000).
   PubMed Web of Science ®Google Scholar
• Sakr Y, Reinhart K, Vincent JL et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely ill Patients (SOAP) Study. Crit. Care Med.34, 589–597 (2006).
   PubMed Web of Science ®Google Scholar
• Hollenberg SM, Ahrens TS, Annane D et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit. Care Med.32, 1928–1948 (2004).
   PubMed Web of Science ®Google Scholar
• Levy B, Bollaert PE, Charpentier C et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med.23, 282–287 (1997).
   PubMed Web of Science ®Google Scholar
• Meier-Hellmann A, Reinhart K, Bredle DL, Specht M, Spies CD, Hannemann L. Epinephrine impairs splanchnic perfusion in septic shock. Crit. Care Med.25, 399–404 (1997).
   PubMed Web of Science ®Google Scholar
• Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet356, 2139–2143 (2000).
   PubMed Web of Science ®Google Scholar
• Kellum JA, M Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit. Care Med.29, 1526–1531 (2001).
   PubMed Web of Science ®Google Scholar
• Landry DW, Levin HR, Gallant EM et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation95, 1122–1125 (1997).
   PubMed Web of Science ®Google Scholar
• Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit. Care Med.31, 1752–1758 (2003).
   PubMed Web of Science ®Google Scholar
• Sharshar T, Carlier R, Blanchard A et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit. Care Med.30, 497–500 (2002).
   PubMed Web of Science ®Google Scholar
• Malay MB, Ashton RC Jr, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J. Trauma47, 699–703 (1999).
   PubMed Web of Science ®Google Scholar
• Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology96, 576–582 (2002).
   PubMed Web of Science ®Google Scholar
• Dunser MW, Mayr AJ, Ulmer H et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation107, 2313–2319 (2003).
   PubMed Web of Science ®Google Scholar
• van Haren FM, Rozendaal FW, van der Hoeven JG. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest124(6), 2256–2260 (2003).
   PubMed Web of Science ®Google Scholar
• Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med.27, 1416–1421 (2001).
   PubMed Web of Science ®Google Scholar
• O’Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet359, 1209–1210 (2002).
   PubMed Web of Science ®Google Scholar
• Morelli A, Rocco M, Conti G et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med.30, 597–604 (2004).
   PubMed Web of Science ®Google Scholar
• Schein RMH, Sprung CL. The use of corticosteroids in the sepsis syndrome. In: Critical Care – State of the Art 1986. Volume 7. Society of Critical Care Medicine, CA, USA, 131–149 (1986).
   Google Scholar
• Sprung CL, Caralis PV, Marcial EH et al. The effect of high-dose corticosteroids in patients with septic shock. N. Engl. J. Med.311, 1137–1143 (1984).
   PubMed Web of Science ®Google Scholar
• Bone RC, Fisher CJ, Clemmer TP et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N. Engl. J. Med.317, 653–658 (1987).
   PubMed Web of Science ®Google Scholar
• The Veterans Administration Systemic Sepsis Cooperative Study Group: effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of sepsis. N. Engl. J. Med.317, 659–665 (1987).
   PubMed Web of Science ®Google Scholar
• Cronin L, Cook DJ, Carlet J et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit. Care Med.23, 1430–1439 (1995).
   PubMed Web of Science ®Google Scholar
• Lefering R, Neugebauser EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit. Care Med.23, 1294–1303 (1995).
   PubMed Web of Science ®Google Scholar
• Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA283, 1038–1045 (2000).
   PubMed Web of Science ®Google Scholar
• Bollaert P-E, Charpentier C, Levy B et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit. Care Med.26, 645–650 (1998).
   PubMed Web of Science ®Google Scholar
• Briegel J, Forst H, Haller M et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit. Care Med.27, 723–732 (1999).
   PubMed Web of Science ®Google Scholar
• Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA288, 862–871 (2002).
   PubMed Web of Science ®Google Scholar
• Keh D, Boehnke T, Weber-Cartens S et al. Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am. J. Respir. Crit. Care Med.167, 512–520 (2003).
   PubMed Web of Science ®Google Scholar
• Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. Br. Med. J.329, 480 (2004).
   PubMed Web of Science ®Google Scholar
• Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann. Intern. Med.141, 47–56 (2004).
   PubMed Web of Science ®Google Scholar
• Marik PE, Zaloga GP. Adrenal insufficiency in the critically ill. Chest122, 1784–1796 (2002).
   PubMed Web of Science ®Google Scholar
• Thaler LM, Blevins LS Jr. The low dose (1-microg) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency. J. Clin. Endocrinol. Metab.83, 2726–2729 (1998).
   PubMed Web of Science ®Google Scholar
• Warren BL, Eid A, Singer P et al. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA286, 1869–1878 (2001).
   PubMed Web of Science ®Google Scholar
• Abraham E, Reinhart K, Opal S et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA290, 238–247 (2003).
   PubMed Web of Science ®Google Scholar
• Faust SN, Levin M, Harrison OB et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N. Engl. J. Med.345, 408–416 (2001).
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent JL, Laterre PF et al. Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med.344, 699–709 (2001).
   PubMed Web of Science ®Google Scholar
• Bernard GR, Margolis BD, Shanies HM et al.; Extended Evaluation of Recombinant Human Activated Protein C United States Investigators. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest125, 2206–2216 (2004).
   PubMed Web of Science ®Google Scholar
• Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N. Engl. J. Med.347, 1030–1034 (2002).
   PubMed Web of Science ®Google Scholar
• Abraham E, Laterre P-F, Garg R et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med.353, 1332–1341 (2005).
   PubMed Web of Science ®Google Scholar
• Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N. Engl. J. Med.345, 1359–1367 (2001).
   PubMed Web of Science ®Google Scholar
• Van den Berghe G, Wilmer A, Hermans G et al. Intensive insulin therapy in the medical ICU. N. Engl. J. Med.354, 449–461 (2006).
   PubMed Web of Science ®Google Scholar
• Levy MM, Pronovost PJ, Dellinger RP et al. Sepsis change bundles: converting guidelines into meaningful change in behavior and clinical outcome. Crit. Care Med.32, S595–S597 (2004).
   PubMedGoogle Scholar